TITLE:
Pleiotropic Effects of GLP-1. Cardiovascular Evidence of Effectiveness
AUTHORS:
Pedro Pujante Alarcón, Ana Belén Hernández Cascales, Alfonso López Ruiz, María Ángeles Ibañez Gil, Alicia Hernández Torres, María Dolores Hellín Gil
KEYWORDS:
GLP-1; T2DM; Myocardium Ischemia
JOURNAL NAME:
Pharmacology & Pharmacy,
Vol.4 No.9,
December
6,
2013
ABSTRACT: Patients with diabetes are
characterized by the development of cardiovascular complications: nephropathy,
retinopathy, neuropathy, ischemia or
hypertensive etc. Therefore, the cardiovascular involvement is the leading
cause of death in patients with Diabetes Mellitus type 2 (DM2). Despite
intensive treatment on classical factors of cardiovascular disease (blood
pressure levels, LDL cholesterol, etc.), patients with diabetes have a high
number of cardiovascular events and the onset and prognosis of these are
related to glycemic control parameters, glycosylated hemoglobin (HbA1c). On the
other hand, the question of
the cardiovascular protective effect of some hypoglycemic treatments has been raised, asking what he has done to know more accurately about the safety
and cardiovascular effects of the treatments we have today. The two most important incretin
hormones are GIP (gastric inhibitory polypeptide) and GLP-1 (glucagon-like
peptide-1). Treatment
based on GLP-1 is a novel weapon in T2DM that achieves a reduction in HbA1c
with other metabolic effects: weight loss and extra effect in dyslipidemia and
blood pressure. In the last
years other beneficial actions such a protector effect against myocardium
ischemia and other actions in basals were reported. In this article we will try to explain the evidence of GLP-1
treatments and its cardiovascular effects.